SARS-CoV-2 is evolving with mutations in the receptor binding domain (RBD) being of
particular concern. It is important to know how much cross-protection is offered between strains …

Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …

Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …

Background GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface protein 3
(MSP3) and glutamate rich protein (GLURP) that mediates an immune response against the …

There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …

Controlled human infections provide opportunities to study the interaction between the
immune system and malaria parasites, which is essential for vaccine development. Here, we …

Background Chloroquine (CQ) has been in use in Africa for a long time. Because of misuse,
this drug has now lost its efficacy due to the emergence of resistance strains in most parts of …

Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in
PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria …

The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and must
be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia virus …

Malaria is still one of the major public health threats in sub-Saharan Africa. An effective
vaccine could be a sustainable control measure that can be integrated into existing health …